GNFT has been the subject of a number of other research reports. HC Wainwright dropped their price target on shares of GENFIT S A/ADR to $72.00 and set a buy rating for the company in a research note on Monday, April 22nd. Stifel Nicolaus began coverage on shares of GENFIT S A/ADR in a report on Tuesday, June 25th. They issued a hold rating for the company. Leerink Swann began coverage on shares of GENFIT S A/ADR in a report on Wednesday, April 24th. They issued an outperform rating and a $25.47 price objective for the company. Svb Leerink began coverage on shares of GENFIT S A/ADR in a report on Wednesday, April 24th. They issued an outperform rating and a $58.00 price objective for the company. Finally, Roth Capital reaffirmed a buy rating on shares of GENFIT S A/ADR in a report on Tuesday, April 23rd. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $45.69.
Shares of NASDAQ:GNFT opened at $15.79 on Thursday. The stock has a fifty day moving average of $18.04. GENFIT S A/ADR has a 12-month low of $14.91 and a 12-month high of $26.25.
About GENFIT S A/ADR
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.
Featured Article: Are all No-Load Funds Equal?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.